Events

EVENTS

News

Janvier 2019 article Biotech Info No91 : "Neuro-Sys : des plantes médicinales pour lutter contre les maladies neurodégénératives."

Neuro-Sys : des plantes médicinales pour lutter contre les maladies neurodégénératives. Son approche repose sur l’usage traditionnel des plantes mais également sur l’étude d’éponges marines pour en extraire les principes actifs efficaces.
Notre recherche a démarré sur les plantes (...)

More

Dec 11, 2018 Information Release : "Neuro-Sys Highlighted Molecules from Sea Sponges to Fight Neurodegenerative Diseases."

By Neuro-Sys SAS Mgmt / December 11, 2018 / News / www.neuro-sys.com
Sea sponges : a new source of natural products that may contain active substances that can be used to treat neurodegenerative diseases, notably Alzheimer’s disease.
GARDANNE, France – December 11, 2018 – (...)

More

11 Déc. 2018 Communiqué : "Des molécules issues d’éponges marines pour combattre les maladies neurodégénératives."

Par Neuro-Sys SAS Mgmt / 11 décembre 2018 / News / www.neuro-sys.com
Nouvelle source de produits naturels pouvant contenir des substances actives pouvant être utilisées dans le traitement des maladies neurodégénératives, notamment la maladie d’Alzheimer : les éponges marines. (...)

More

30/10/2018 Article La Provence : "Les plantes pour ralentir les maladies neurodégénératives."

Les plantes pour ralentir les maladies neurodégénératives.
Les recherches de la start-up gardannaise Neuro-Sys se concrétisent.
Charcot, Alzheimer, Parkinson, les maladies neurodégénératives sont nombreuses et d’une dureté effroyable. A Gardanne, la start-up Neuro-Sys a déjà déposé (...)

More

Posters

MNDA 2018 - ALS

7-9 December 2018, Glasgow (UK)
Translocation of TDP-43 and FUS in cortical neurons and spinal motor neurons after glutamatergic stress or in presence of the neurotoxic peptide Aβ1-42.

Download

ISCNP 2018 - AD (NSP01)

25-29 November 2018, Athens (Greece)
From traditional use to standardized neuroprotective green-extract of Huperzia serrata.

Download

MNM 2018 - ER STRESS

04-05 October 2018, Munich (Germany)
Activation of the PERK pathway reduces the proteinopathy associated with neurodegenerative diseases : evidence from in vitro models of AD, PD and ALS.

Download

IAPRD 2018 - PD

19-22 August 2018, Lyon (France)
Acute dopaminergic neurotoxicity of alphasynuclein oligomers is mediated by microglial cells.

Download

IAPRD 2018 - PD (SNC1)

19-22 August 2018, Lyon (France)
Neuroprotective effects of SNC-1 (Ethnodyne Neuro®), a natural product used in ayurvedic traditional medicine, on in vitro models of Parkinson’s disease.

Download

SOCIETE DES NEUROSCIENCES - AD

7-8 June 2018, Strasbourg (France)
ER-stress regulation and effect of Guanabenz in primary cortical neurons injured with Aβ1-42 peptide, an in vitro model of Alzheimer’s disease.

Download

AAT-AD/PD 2018 - AD

15-18 March 2018, Torino (Italy)
A new treatment for Alzheimer’s disease : AZP2006 prevents and reverses amyloid and Tau damages via release of one growth factor and reduction of neuroinflammation.

Download

MNM 2017 - PD (SNC1)

28-29 September 2017, London (UK)
SNC-1 a natural food supplement, a promising candidate for the treatment of Parkinson’s Disease.

Download

MNM 2017 - BBB

28-29 September 2017, London (UK)
Effects of circulating and neuronal amyloid peptide oligomers on BBB integrity : consequences for the disease.

Download

AAIC 2017 - BBB

16-20 July 2017, London (UK)
Effects of circulating and neuronal amyloid peptide oligomers on the BBB integrity : consequences on the neurodegeneration process.

Download

AD/PD 2017 - PD

29 March - 02 April 2017, Vienna (Austria)
MPP+ induced dopaminergic neuron death through necroptosis and autophagy.

Download

AD/PD 2017 - ALS

29 March - 02 April 2017, Vienna (Austria)
Amyloid peptide and cytoplasmic TDP-43 accumulation in pathogenesis of ALS : an in vitro study.

Download

MNM 2016 - AD/BBB

29-30 September 2016, London (UK)
A novel triple cell co-culture model for mimicking the BBB into normal or pathological situations.

Download

AAIC 2016 - AD

22-28 July 2016, Toronto (Canada)
Mode of action study of NSP01-E, a potential treatment for Alzheimer’s disease, in protection against amyloid β peptide (Aβ) injury.

Download

MYOLOGY 2016 - ALS

14-18 March 2016, Lyon (France)
Pathological role of amyloid peptide in neuromuscular disease, glutamate and glucose involvement.

Download

JSFM 2015 - ALS

23-25 November 2015, Lyon (France)
Deleterious effects of amyloid beta peptide in the neuromuscular junction : consequences in ALS disease.

Download

PHYT’AROM 2015 - SNC-1

5-7 June 2015, Grasse (France)
Neuroprotective effect of SNC-1 a natural plant extract. Promising treatment for Alzheimer’s and Parkinson’s disease ?

Download

AD/PD 2015 - PD

18-22 March 2015, Nice (France)
α-synuclein : cause or consequence of cytopathological lesions observed in in vitro models of Parkinson’s disease.

Download

AD/PD 2015 - AD

18-22 March 2015, Nice (France)
Neurodegeneration induced by Aβ oligomeric fractions : role of NMDA receptors and mGluR5.

Download

ARUK CONF. 2015 - AD

10-11 March 2015, London (UK)
NSP01-E01 and NSP01-C01 : new preparations able to protect from beta-amyloid peptide (Aβ) injuries. Potential treatments for Alzheimer’s disease.

Download

SFN 2014 - PD

15-19 November 2014, Washington (USA)
Study of mitochondrial death pathways in different cellular models of Parkinson’s disease : effect of 17β-Estradiol.

Download

SFN 2014 - AD

15-19 November 2014, Washington (USA)
Beta-estradiol protects cortical neurons from beta-amyloid oligomers toxicity through mediations of the Ras/raf and PI3K pathways.

Download

ICNMD 2014 - ALS

5-10 July 2014, Nice (France)
Role of β-Amyloid (Aβ) Oligomeric fractions in ALS disease.

Download

Publications